Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen

Brain Res Mol Brain Res. 1999 Apr 6;67(1):148-57. doi: 10.1016/s0169-328x(99)00053-4.

Abstract

The purpose of the present study was to examine the time-related effects of repeated administration of Delta9-tetrahydrocannabinol during 1, 3, 7 and 14 days on cannabinoid and mu-opioid receptor agonist-stimulated [35S]GTPgammaS binding, and CB1 cannabinoid receptor and proenkephalin gene expression in the caudate-putamen. Repeated administration with Delta9-tetrahydrocannabinol produced a time-related reduction in cannabinoid receptor synthesis and activation of signal transduction mechanisms in the caudate-putamen. Indeed, WIN-55,212-2-stimulated [35S]GTPgammaS binding decreased 24% on day 1 and then progressively decreased finding a 42% decrease on day 14. Similarly, CB1 cannabinoid receptor mRNA levels decreased (22%) on day 3, reaching 50% reduction on day 7. In contrast, a pronounced increase is detected in DAMGO-stimulated [35S]GTPgammaS binding and proenkephalin mRNA levels in the caudate-putamen. The highest degree of increase was reached on day 7 of the treatment (35% of proenkephalin mRNA levels and 62% of DAMGO-stimulated [35S]GTPgammaS binding) and then values slightly decreased on day 14. Taken together, the results of the present study indicate that, in the caudate-putamen, repeated administration with Delta9-tetrahydrocannabinol produces a time-related increase in proenkephalin gene expression and mu-opioid receptor activation of G-proteins, and a time-related decrease in CB1 cannabinoid receptor gene expression and reduction in CB1 cannabinoid receptor activation of G-proteins. These results also suggest a possible interaction between the cannabinoid and opioid systems in the caudate-putamen which may be potentially relevant in the understanding of the alterations of motor behavior that occur after prolonged exposure to cannabinoids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Analgesics, Opioid / pharmacology
  • Animals
  • Benzoxazines
  • Dronabinol / pharmacology*
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • Enkephalins / genetics*
  • Enkephalins / pharmacology
  • GTP-Binding Proteins / physiology
  • Gene Expression / drug effects
  • Guanosine 5'-O-(3-Thiotriphosphate) / pharmacology
  • In Situ Hybridization
  • Male
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Neostriatum / chemistry
  • Neostriatum / physiology
  • Protein Precursors / genetics*
  • Psychotropic Drugs / pharmacology*
  • RNA, Messenger / analysis
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cannabinoid
  • Receptors, Drug / genetics*
  • Receptors, Opioid, mu / physiology*
  • Sulfur Radioisotopes
  • Time Factors

Substances

  • Analgesics
  • Analgesics, Opioid
  • Benzoxazines
  • Enkephalins
  • Morpholines
  • Naphthalenes
  • Protein Precursors
  • Psychotropic Drugs
  • RNA, Messenger
  • Receptors, Cannabinoid
  • Receptors, Drug
  • Receptors, Opioid, mu
  • Sulfur Radioisotopes
  • proenkephalin
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • Guanosine 5'-O-(3-Thiotriphosphate)
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Dronabinol
  • GTP-Binding Proteins